+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents



Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents



Cutis 81(2): 171-178



Two 12-week, randomized, vehicle-controlled. double-blinded pivotal studies and a 12-month. long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37%) were adolescents aged 12 to 15 years and comprised the subgroup reported here. Participants randomly were assigned to twice-daily treatment with dapsone gel (n=578) or vehicle gel (n=547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n=181). In the pivotal studies, success based on achieving a Global Acne Assessment Score (GAAS) of 0 (none) or 1 (minimal) at week 12 was significantly greater for the dapsone gel-treated adolescent participants (40.1%; 232/578) compared with the vehicle gel-treated adolescent participants (28.2%; 154/547) (P<.001). Treatment with dapsone gel in adolescents also resulted in clinically meaningful improvements in acne lesion counts by week 12 in the pivotal studies and for up to 12 months in the long-term safety study. The incidence of adverse events, including application-site events, was low and similar between treatment groups in the pivotal studies and was similarly low in the long-term safety study. Results from the large number of adolescent participants in these 3 studies show that dapsone gel is an effective and safe topical therapy for the treatment of acne vulgaris in adolescents aged 12 to 15 years for up to 12 months.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052895779

Download citation: RISBibTeXText

PMID: 18441772


Related references

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials. Journal of Drugs in Dermatology 15(5): 553-561, 2017

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. Journal of Drugs in Dermatology 15(8): 962-969, 2017

Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. American Journal of Clinical Dermatology 10(4): 221-227, 2009

Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. Journal of the American Academy of Dermatology 56(3): 439.E1-10, 2007

Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. Journal of Drugs in Dermatology 6(10): 981-987, 2007

Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype. Journal of Drugs in Dermatology 17(2): 160-167, 2018

The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color. Journal of Drugs in Dermatology 15(2): 197-204, 2017

Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Archives of Dermatology 144(12): 1564-1570, 2008

Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris. Yearbook of Dermatology and Dermatologic Surgery 2010: 286-287, 2010

Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials. Journal of Clinical and Aesthetic Dermatology 9(10): 18-27, 2016

Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment. Journal of Drugs in Dermatology 15(2): 191-195, 2017

Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris. Journal of Drugs in Dermatology 15(10): 1250-1259, 2017

Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clinical, Cosmetic and Investigational Dermatology 6: 123-125, 2013

Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. British Journal of Dermatology 124(4): 368-371, 1991

The efficacy and safety of gamma-linolenic acid for the treatment of acne vulgaris. International Journal of Dermatology 53(3): E199-E200, 2014